Neuropsychiatric symptoms in early stage of Alzheimer’s and non-Alzheimer’s dementia, and the risk of progression to severe dementia
Author(s) -
Tau Ming Liew
Publication year - 2021
Publication title -
age and ageing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.014
H-Index - 143
eISSN - 1468-2834
pISSN - 0002-0729
DOI - 10.1093/ageing/afab044
Subject(s) - dementia , medicine , apathy , irritability , clinical dementia rating , interquartile range , alzheimer's disease , psychiatry , disease , anxiety
Background Neuropsychiatric symptoms (NPSs) in early dementia have been suggested to predict a higher risk of dementia progression. However, the literature is not yet clear whether the risk is similar across Alzheimer's dementia (AD) and non-Alzheimer's dementia (non-AD), as well as across different NPSs. This study examined the association between NPSs in early dementia and the risk of progression to severe dementia, specifically in AD and non-AD, as well as across various NPSs. Method This cohort study included 7,594 participants who were ≥65 years and had early dementia (global Clinical Dementia Rating [CDR] = 1). Participants completed Neuropsychiatric-Inventory–Questionnaire at baseline and were followed-up almost annually for progression to severe dementia (global CDR = 3) (median follow-up = 3.5 years; interquartile range = 2.1–5.9 years). Cox regression was used to examine progression risk, stratified by AD and non-AD. Results The presence of NPSs was associated with risk of progression to severe dementia, but primarily in AD (HR 1.4, 95% confidence interval [CI]: 1.1–1.6) and not in non-AD (HR 0.9, 95% CI: 0.5–1.5). When comparing across various NPSs, seven NPSs in AD were associated with disease progression, and they were depression, anxiety, apathy, delusions, hallucinations, irritability and motor disturbance (HR 1.2–1.6). In contrast, only hallucinations and delusions were associated with disease progression in non-AD (HR 1.7–1.9). Conclusions NPSs in early dementia—especially among individuals with AD—can be useful prognostic markers of disease progression. They may inform discussion on advanced care planning and prompt clinical review to incorporate evidence-based interventions that may address disease progression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom